Proposal for the development of biologics in pediatric rheumatology

Area of Science:

• Pediatric Rheumatology
• Drug Development
• Clinical Trials

Background:

• Assessing the development, approval, and clinical introduction of biologics for pediatric rheumatic diseases in Japan.
• Noting reduced review and approval times by the Pharmaceuticals and Medical Devices Agency.
• Identifying clinical trial duration as a bottleneck in biologic development.

Purpose of the Study:

• To describe the current status of biologic anti-rheumatic agent development for children in Japan.
• To identify challenges and propose future directions for early clinical practice introduction.
• To focus on strategies for promoting biologic development and early use.

Main Methods:

• Analysis of the development and approval process for pediatric biologics in Japan.
• Focus on keywords: registry, centralization, and global cooperation.
• Proposal for improving clinical trial duration.

Main Results:

• Review periods for clinical trials and approval have decreased.
• Clinical trial duration is the rate-limiting step for development to approval.
• Registry, centralization, and global cooperation are crucial for shortening trial duration.

Conclusions:

• Establishing a world-scale registry system is essential for reducing clinical trial duration.
• Developing the existing Japanese Pediatric Rheumatology Association registry is a key step.
• Participating in international networks and conducting global cooperative trials with sufficient Japanese enrollment is vital.